Skip to main content

Fiscal Wizard · Single-issue tearsheet

BDX / Aug 13, 2026 Run #13792

BDX

Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Composite verdict

F 27.8 / 100
Gated stand-aside 0 drivers · 3 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 7th of 8 in Medical Instruments & Supplies

rescore-sweep
Technical synthesisRegime: uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -47%
Asset value $93.21Earnings power value $31.51Price $183.58

Priced above its no-growth earnings power value ($31.51/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

27.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
P/B 75
PEGY 0
EV/EBITDA 73
Margin of Safety 0
EV/FCF 68
OCF to Net Income 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 44 signals shown.

Risk Gates

3 blocking 10 caution

3 guards active, 44 signals gated.

Earnings Event Blackout Blocking

Mutes all technical signals within the earnings announcement window when earnings dates are available.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BDX.